Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Leases: 2020-2024

Historic Operating Leases for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $28.1 million.

  • Foghorn Therapeutics' Operating Leases fell 25.65% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 25.65%. This contributed to the annual value of $28.1 million for FY2024, which is 37.74% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Operating Leases of $28.1 million as of FY2024, which was down 37.74% from $45.1 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Operating Leases high stood at $62.3 million for FY2020, and its period low was $28.1 million during FY2024.
  • Its 3-year average for Operating Leases is $41.5 million, with a median of $45.1 million in 2023.
  • Data for Foghorn Therapeutics' Operating Leases shows a maximum YoY crashed of 37.74% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Operating Leases stood at $62.3 million in 2020, then fell by 6.43% to $58.3 million in 2021, then declined by 11.70% to $51.5 million in 2022, then fell by 12.49% to $45.1 million in 2023, then slumped by 37.74% to $28.1 million in 2024.